FDA approves high-dose Fluzone for older patients

12/23/2009 | Reuters

Sanofi Pasteur secured FDA approval to promote a high-dose formulation of its Fluzone seasonal flu vaccine for people 65 and older. Sanofi's application was supported by clinical data showing the superiority of high-dose Fluzone over its original formulation in eliciting an immune response.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA